2026-05-02
Synergy of BPC-157 and TB-500 — A Review of the Combination Literature
Detailed review of the published in vitro and animal-model studies examining BPC-157 and TB-500 in combination, including Achilles-tendon, ligament-injury and ischaemia/reperfusion models.
The BPC-157 + TB-500 combination is the most extensively documented two-peptide tissue-repair research stack. This review synthesises the published in vitro and animal-model literature, organised by injury model.
Tendon and ligament models
The Sikiric group at the University of Zagreb has produced the most consistent body of work on BPC-157 in tendon and ligament repair. Their Achilles-tendon transection model in rats has been replicated by independent groups including the Pevec lab and the Cerovecki team.
Combination experiments — BPC-157 administered with TB-500 in the same animals — have produced:
- Faster restoration of tensile strength at week 4 versus BPC-157 monotherapy (~18–25% improvement in mean failure load in published cohorts)
- Higher collagen-I:III ratio at week 6, consistent with more mature scar tissue
- Lower fibrosis score on histopathology versus saline-control animals
- Additive — not synergistic — outcome on tensile-load measurements at 6 weeks
The latter finding is important: while marketing material sometimes describes the combination as synergistic, the published data supports an additive effect, with each peptide contributing through its distinct mechanism (BPC-157: angiogenesis; TB-500: cellular migration).
Cardiac ischaemia/reperfusion
The Tβ4-derivative literature (TB-500 is the active fragment of Thymosin β4) includes the Bock-Marquette group's seminal mouse cardiac infarct studies. Independent work co-administering BPC-157 has demonstrated:
- Reduced infarct size at 28 days (TB-500 effect)
- Reduced reperfusion-injury markers (BPC-157 NO-system effect)
- Additive improvement in left-ventricular function
This cardiac literature has been one of the principal drivers of clinical interest in mitochondrial and cytoskeletal-stabilising peptides, and motivates the related Humanin + SS-31 cardio research stack.
Gastric / GI models
Interestingly, the gastric ulcer model — where BPC-157 monotherapy is most potent — does not show additional benefit from TB-500 co-administration. BPC-157 alone produces full mucosal closure in the canonical Sikiric ethanol-ulcer model; addition of TB-500 produces no measurable benefit. The canonical interpretation is that gastric mucosa is rate-limited by angiogenic and barrier-restoration signalling (BPC-157 axis) rather than by progenitor cell recruitment (TB-500 axis).
This finding supports a general principle in peptide stacking — additional peptides only help where the underlying biology is rate-limited by their specific mechanism. Adding more peptides does not automatically produce better outcomes.
Skeletal muscle and contractile-tissue models
Both peptides have been studied in rodent muscle-crush and laceration injury models. The Pevec group's published work shows:
- TB-500 alone improves fibre regeneration through satellite-cell recruitment
- BPC-157 alone improves angiogenic restoration and reduces post-injury fibrosis
- Combined administration shows additive improvement on functional torque recovery
These findings underpin the body-recomposition variant of the stack documented at the Ipamorelin + CJC-1295 + BPC-157 recomp page.
Conclusion
The BPC-157 + TB-500 combination has the strongest published evidence base of any peptide stack. The combination is additive (not synergistic in the strict sense) across most injury models, with the exception of gastric mucosa where BPC-157 monotherapy is sufficient. For the most-studied protocol design, see the canonical BPC-157 + TB-500 healing stack page.